Korea Brain Research Institute Identifies How TDP-43 Disrupts the Antioxidant Defense System
Increasing Antioxidant Protein Reduces Neuronal Toxicity... Potential New Therapeutic Target

A new pathway has been identified through which a protein that abnormally clumps in the brains of patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia disrupts neurons' defense systems and causes damage. Korean researchers confirmed that the protein interferes with the production of an antioxidant protein that protects cells, and successfully reduced neuronal toxicity by increasing the antioxidant protein. Although the research is still at the cellular level, it is being seen as pointing to a new therapeutic target for intractable neurodegenerative brain diseases.


The Korea Brain Research Institute (KBRI) said Wednesday that a team led by senior researchers Kim Jaekwang and Nam Minyeop of its Department of Brain Disease Research had identified a new molecular pathway involved in neuronal damage in ALS and frontotemporal dementia. The team collaborated with a group led by principal researcher Kim Cheona of the Korea Research Institute of Bioscience and Biotechnology, Professor Lee Sangwon of Korea University, and Professor Kim Sangryong of Kyungpook National University. The findings were published in the international journal Redox Biology.

When TDP-43 protein abnormally accumulates in the cytoplasm, it suppresses production of the antioxidant protein Trx1, causing oxidative stress and mitochondrial dysfunction that damage neurons. Conversely, increasing Trx1 can reduce protein aggregation and neuronal damage. Courtesy of the research team.

When TDP-43 protein abnormally accumulates in the cytoplasm, it suppresses production of the antioxidant protein Trx1, causing oxidative stress and mitochondrial dysfunction that damage neurons. Conversely, increasing Trx1 can reduce protein aggregation and neuronal damage. Courtesy of the research team.

View original image

ALS is a disease in which motor neurons gradually become damaged, making it difficult to move muscles. Frontotemporal dementia is a neurodegenerative brain disease that impairs functions such as behavior and language as the brain's frontal and temporal lobes become damaged.


A common finding in both diseases is the abnormal aggregation of the TDP-43 protein. Under normal conditions, TDP-43 regulates the processing of genetic information in the cell nucleus, but when disease develops, it moves into the cytoplasm and forms clumps. These aggregates are observed in about 97% of patients with ALS and about half of patients with frontotemporal dementia. However, the specific process by which the aggregates damage neurons has not been fully understood.


The research team focused on thioredoxin-1 (Trx1), an antioxidant protein that protects cells from oxidative stress. Their analysis showed that abnormally aggregated TDP-43 traps the messenger ribonucleic acid (mRNA) needed to produce Trx1 inside the aggregates, thereby disrupting protein production.


A shortage of Trx1 disrupts the balance between oxidation and reduction inside cells and also impairs the function of mitochondria, which produce energy. This ultimately increases oxidative stress and leads to neuronal damage.


Increasing Antioxidant Protein Reduces Neuronal Toxicity


The research team found that increasing Trx1 levels in mouse neurons reduced TDP-43 aggregation and neuronal toxicity. They also increased Trx1 expression in motor neurons derived from induced pluripotent stem cells from a person with a TDP-43 gene mutation associated with ALS, and found that oxidative stress and protein aggregation decreased.

Photo courtesy of KBRI.

Photo courtesy of KBRI.

View original image

This shows that restoring the antioxidant defense system weakened by TDP-43 aggregation may help protect neurons. However, further validation through animal studies and clinical trials is needed to determine whether the approach is effective as a treatment for patients.



"We have shown that TDP-43 clumps are not simply traces of disease, but active perpetrators that directly disable the cell's defense system," said Kim Jaekwang, a senior researcher at the Korea Brain Research Institute. "We hope that restoring Trx1 will lead to a new treatment strategy for ALS and other TDP-43-related neurodegenerative diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing